PULMONARY EMBOLISM: SOME ISSUES OF EPIDEMIOLOGY AND TREATMENT IN CANCER PATIENTS
The risk of pulmonary embolism (PE) in cancer patients is 4–7-fold, compared to other patient categories. PE is the second most frequent cause of death in the first year after cancer diagnosis. PE is diagnosed in 7.5% of patients with malignant brain tumors, in 1 to 25% of those with gastroi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
MONIKI
2016-02-01
|
| Series: | Alʹmanah Kliničeskoj Mediciny |
| Subjects: | |
| Online Access: | https://www.almclinmed.ru/jour/article/view/84 |
| _version_ | 1818431518871126016 |
|---|---|
| author | I. D. Rozanov A. E. Semashkova A. S. Balkanov S. A. Terpigorev E. A. Stepanova |
| author_facet | I. D. Rozanov A. E. Semashkova A. S. Balkanov S. A. Terpigorev E. A. Stepanova |
| author_sort | I. D. Rozanov |
| collection | DOAJ |
| description | The risk of pulmonary embolism (PE) in cancer patients is 4–7-fold, compared to other patient categories. PE is the second most frequent cause of death in the first year after cancer diagnosis. PE is diagnosed in 7.5% of patients with malignant brain tumors, in 1 to 25% of those with gastrointestinal tumors, in 4.5 to 17.5% of those with breast cancer and in 4 to 10% of lung cancer patients. The risk of PE is higher with surgical interventions and chemotherapy, as well as in metastatic tumors. In 13% of cases, PE may be the first symptom of cancer manifestation. For prevention and treatment of PE low molecular weight heparin (LMWH) and warfarin are used. The risk of recurrent PE is 2-fold lower with LMWH. The frequency of bleeding with LMWH and warfarin treatment is from 14 to 19%. Placement of a cava filter is indicated only if anticoagulation is inefficient. New oral anticoagulants, which act as selective thrombin or Factor Xa inhibitors, are not used in cancer patients. Thus, diagnostics and treatment of PE is a very urgent problem in oncology that requires new approaches to be looked for. |
| first_indexed | 2024-12-14T15:50:35Z |
| format | Article |
| id | doaj.art-05f501ba1352475cb0bf1b6f2b1a56ac |
| institution | Directory Open Access Journal |
| issn | 2072-0505 2587-9294 |
| language | Russian |
| last_indexed | 2024-12-14T15:50:35Z |
| publishDate | 2016-02-01 |
| publisher | MONIKI |
| record_format | Article |
| series | Alʹmanah Kliničeskoj Mediciny |
| spelling | doaj.art-05f501ba1352475cb0bf1b6f2b1a56ac2022-12-21T22:55:23ZrusMONIKIAlʹmanah Kliničeskoj Mediciny2072-05052587-92942016-02-010419710210.18786/2072-0505-2015-41-97-10284PULMONARY EMBOLISM: SOME ISSUES OF EPIDEMIOLOGY AND TREATMENT IN CANCER PATIENTSI. D. Rozanov0A. E. Semashkova1A. S. Balkanov2S. A. Terpigorev3E. A. Stepanova4Moscow Regional Research and Clinical InstituteMoscow Regional Research and Clinical InstituteMoscow Regional Research and Clinical InstituteMoscow Regional Research and Clinical InstituteMoscow Regional Research and Clinical InstituteThe risk of pulmonary embolism (PE) in cancer patients is 4–7-fold, compared to other patient categories. PE is the second most frequent cause of death in the first year after cancer diagnosis. PE is diagnosed in 7.5% of patients with malignant brain tumors, in 1 to 25% of those with gastrointestinal tumors, in 4.5 to 17.5% of those with breast cancer and in 4 to 10% of lung cancer patients. The risk of PE is higher with surgical interventions and chemotherapy, as well as in metastatic tumors. In 13% of cases, PE may be the first symptom of cancer manifestation. For prevention and treatment of PE low molecular weight heparin (LMWH) and warfarin are used. The risk of recurrent PE is 2-fold lower with LMWH. The frequency of bleeding with LMWH and warfarin treatment is from 14 to 19%. Placement of a cava filter is indicated only if anticoagulation is inefficient. New oral anticoagulants, which act as selective thrombin or Factor Xa inhibitors, are not used in cancer patients. Thus, diagnostics and treatment of PE is a very urgent problem in oncology that requires new approaches to be looked for.https://www.almclinmed.ru/jour/article/view/84pulmonary embolismcancer patientlow molecular weight heparinwarfarin |
| spellingShingle | I. D. Rozanov A. E. Semashkova A. S. Balkanov S. A. Terpigorev E. A. Stepanova PULMONARY EMBOLISM: SOME ISSUES OF EPIDEMIOLOGY AND TREATMENT IN CANCER PATIENTS Alʹmanah Kliničeskoj Mediciny pulmonary embolism cancer patient low molecular weight heparin warfarin |
| title | PULMONARY EMBOLISM: SOME ISSUES OF EPIDEMIOLOGY AND TREATMENT IN CANCER PATIENTS |
| title_full | PULMONARY EMBOLISM: SOME ISSUES OF EPIDEMIOLOGY AND TREATMENT IN CANCER PATIENTS |
| title_fullStr | PULMONARY EMBOLISM: SOME ISSUES OF EPIDEMIOLOGY AND TREATMENT IN CANCER PATIENTS |
| title_full_unstemmed | PULMONARY EMBOLISM: SOME ISSUES OF EPIDEMIOLOGY AND TREATMENT IN CANCER PATIENTS |
| title_short | PULMONARY EMBOLISM: SOME ISSUES OF EPIDEMIOLOGY AND TREATMENT IN CANCER PATIENTS |
| title_sort | pulmonary embolism some issues of epidemiology and treatment in cancer patients |
| topic | pulmonary embolism cancer patient low molecular weight heparin warfarin |
| url | https://www.almclinmed.ru/jour/article/view/84 |
| work_keys_str_mv | AT idrozanov pulmonaryembolismsomeissuesofepidemiologyandtreatmentincancerpatients AT aesemashkova pulmonaryembolismsomeissuesofepidemiologyandtreatmentincancerpatients AT asbalkanov pulmonaryembolismsomeissuesofepidemiologyandtreatmentincancerpatients AT saterpigorev pulmonaryembolismsomeissuesofepidemiologyandtreatmentincancerpatients AT eastepanova pulmonaryembolismsomeissuesofepidemiologyandtreatmentincancerpatients |